ERBB2 and breast carcinoma: Another agent promising for targetedradionuclide diagnosis of HER2-positive breast cancer is a designed ankyrinrepeat protein (DARPinG3) molecule that is constructed on the basis of 14 to 21kDa ankyrin proteins and exhibits a high tropism for epidermal growth factorreceptor type 2 [16].